TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01320813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted thyroidectomy
Description: Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open thyroidectomy
Description: Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
Study: NCT04620616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject Usual Brand ENDS
Description: Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject Usual Brand ENDS
Description: Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
Study: NCT01422603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
Study: NCT00377104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01821404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Capsules including 80 mg of atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar capsules as in the atorvastatin arm, but without the active ingredient
Study: NCT01613508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach
Study: NCT04620616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject Usual Brand ENDS
Description: Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
Study: NCT01613508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Posterior Approach
Study: NCT00647946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir DF
Description: tenofovir DF 300mg once daily along with the other antiviral drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir 300mg twice daily
Description: abacavir 300mg twice daily along with the other antiviral drugs
Study: NCT01040689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744) Low
Description: Low dose inhaled orally once daily from Respimat inhaler
Study: NCT00005969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin Liposome
Description: Liposome by vein (IV) over 30 minutes every other day for 28 days
Study: NCT01757587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: 50 mg, 2 tablets/day on 3 months, both periods of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg 2 tablets / day on 3 months, both periods of treatment
Study: NCT03779633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linoladiol Estradiol
Description: Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal cream
Description: Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks
Study: NCT01040689

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for olodaterol BI1744)
Description: Placebo (olodaterol low and high dose)delivered by Respimat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Tiotropium)
Description: Placebo (Tiotropium 18 mcg) delivered by HandiHaler
Study: NCT01734278

Intervention type: OTHER
Intervention: No intervention
Description: This is a non-interventional study.
Study: NCT02197598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalmefene
Study: NCT04745468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP apheresis
Description: Selective CRP apheresis by use of the PentraSorb-CRP adsorber
Study: NCT00930709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A (Botox®, Allergan)
Description: Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
Study: NCT00930709

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active strength training and stretching
Description: Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
Study: NCT03966729

Intervention type: OTHER
Intervention: Time (outcome)

Intervention type: OTHER
Intervention: Time (outcome)

Intervention type: OTHER
Intervention: Time (outcome)
Study: NCT01708538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXL
Description: corneal crosslinking

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXL
Description: corneal crosslinking
Study: NCT02690168

Intervention type: BEHAVIORAL
Intervention: Fasting
Description: 72 hour fasting
Study: NCT01233180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gua Sha
Description: Single Gua Sha treatment of the neck and shoulder region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermotherapy
Description: Single use of a mud heat pad on the neck and shoulder region
Study: NCT06134869

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone augmentation
Description: Dense PTFE membranes covering an allograft biomaterial were used without any attempt to passivate the flap
Study: NCT03460288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retraining (AAT)
Description: The training program is based upon the approach-avoidance task (AAT) and can be easily performed on a computer, laptop or tablet. There is a total of 20 pictures, 10 slot-machine gambling related pictures and 10 neutral pictures that were already used in a prior study (Wittekind et al., submitted). The pictures appear on the computer screen and have to be either pushed or pulled. Pushing and pulling depends on a masked instruction (not related to the content of the pictures, but to the color of the frame). All gambling-related pictures are framed with the color that is instructed to be pushed, all neutral pictures are framed with the color that is instructed to be pulled.
Study: NCT03698422

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine samples
Description: Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
Study: NCT01040689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744) High
Description: High dose inhaled orally once daily from Respimat inhaler
Study: NCT03698422

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine samples
Description: Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine samples
Description: Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
Study: NCT04820153

Intervention type: DEVICE
Group type: OTHER
Intervention: Physical Activity Monitoring Device
Description: Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Redesign Coaching
Description: Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
Study: NCT01666145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced Image Guidance
Description: Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
Study: NCT01517412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-injector pen device (OptiClik®)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-injector pen device (OptiClik®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: To be kept at stable dose (≥1.5 g/day) throughout the study.
Study: NCT02289365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2000 mg of JBM-TC4 per day
Description: 2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3000 mg of JBM-TC4 per day
Description: 3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
Study: NCT00754403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and metformin
Description: Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
Study: NCT02289365

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3000 mg of PEG-400 per day
Description: 3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
Study: NCT02284256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrocaps

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil
Study: NCT01517412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: To be kept at stable dose (≥1.5 g/day) throughout the study.
Study: NCT03002285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cerebral Palsy group
Description: Group with Cerebral Palsy that performed the Fitts law in a computer task

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Group with typical development that performed the Fitts law in a computer task
Study: NCT00909519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod
Description: naproxcinod 750 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: furosemide
Study: NCT00055575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Nasal Spray
Study: NCT02122926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive discharge intervention
Description: The intervention is a multi-modal program consisting of the following:~1. Inpatient protocol for adjusting the discharge diabetes regimen;~2. Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~3. Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~4. Visiting nurse intervention after discharge;~5. Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~6. Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~7. Follow-up with PCP or endocrinologist within 1 week of discharge.
Study: NCT03134612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain 40 mg
Study: NCT00586638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game based training
Description: 36 one-hour sessions over 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video game based training
Description: 36 one-hour sessions over 12 weeks
Study: NCT03774368

Intervention type: OTHER
Group type: OTHER
Intervention: Emergency contraception website
Description: Existing website with factual information about emergency contraception

Intervention type: OTHER
Group type: OTHER
Intervention: Emergency contraception video
Description: Existing video with factual information about emergency contraception
Study: NCT02335203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Description: One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
Study: NCT01295307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Induction and consolidation therapy / conditioning therapy with Clofarabine
Study: NCT02954887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT03271320

Intervention type: OTHER
Intervention: appearance scales
Description: appearance scales : AVS; ASWAP; DAS 59

Intervention type: OTHER
Intervention: appearance scales
Description: appearance scales : AVS; ASWAP; DAS 59
Study: NCT04092803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The system includes a VR headset with VR software already loaded in to it.
Study: NCT00768261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine (Namenda®)
Description: Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil (Aricept®)
Description: 5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil (Aricept®)
Description: 5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
Study: NCT02148263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Study: NCT01040689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg
Description: 18mcg inhaled once daily from Handihaler
Study: NCT04174768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
Study: NCT01293084

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.12% saline
Description: 5mL of 0.12% saline inhaled once over 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% saline
Description: 5mL 7% saline inhaled once over 20 minutes
Study: NCT01877941

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Artery Catheter (PAC)
Description: A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Cardiac Output Monitor (ECOM)
Description: An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Estimated Continuous Cardiac Output (esCCO)
Description: Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
Study: NCT02796612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: Patients do not receive any interventions but are treated according to current standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Description: Patients do not receive any interventions but are treated according to current standard of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delivery of a take-home brochure
Description: Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient care by a psychologically trained physician
Description: The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
Study: NCT04712487

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological culture, viral PCR, histopathological analysis
Description: Intervertebral disc tissue was sent to the laboratory for further analysis:~Microbiological culture: Detection of bacterial growth Viral PCR: Detection of Herpes-Simplex-Type 1 virus, Herpes-Simplex-Type 2 virus, Cytomegalovirus Histopathological analysis: Inflammation signs of disc tissue
Study: NCT02685111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-filgrastim
Description: Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
Study: NCT04035538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-320, D012
Description: R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-320, D012
Description: R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO